You were right about the share price. 2014 was not a good year for the share price.
However:
Like the rest of us you have no idea what will trigger an early look-in for the Sunrise trial. Or for that matter whether Bavi is helping these desperately sick people.
Like the rest of us you have no idea if any BPs are seriously interested in partnering Bavi or buying Peregrine.
Like the rest of us you have no idea what the dozens of Bavi preclinical collaborations will generate.
Like the rest of us you have no idea when the Bavi-Yervoy open label trial will generate any news.
Like the rest of us you have no idea why Peregrine is expanding Avid's production capacity.
It is matters like the above that will determine Peregrine's 2015 prospects.
One thing we can all be sure of 2015 will be eventful. My share price prediction is a range $.10 to $10.0. I think the SP will finish closer to latter.
News 
Market Data 
Discover 
